SELL BMY with modified execution: trim 20-30% at market, stop at $61 or use put hedge, hold cash/Treasuries (do not rotate to Pfizer)

• Q2 fundamentals intact: revenue $12.97B (highest in dataset), up 5.7% YoY, gross margin 71.6%, operating margin 34.4%, FCF $12-14B annually
• Normalized EPS ~$1.27/quarter (after $0.75 haircut for restructuring collapse) implies $5+ annualized run rate, keeping forward multiple in 12-13x range
• VWMA at $66.53 still rising - signature of pullback within intact uptrend, not structural decline; Bollinger middle band at $66.24 supports mean-reversion bounce scenario
• Pfizer rotation offers 200bps yield pickup (5.91% vs 3.91%) but introduces correlated sector risk, not risk reduction
• Current price $63.75 with 50 SMA at $63.27 and lower Bollinger at $63.38 - probability of clean rally to $66 before breakdown is low
• ATR of $1.50 makes $57.60 stop (200 SMA) vulnerable to single-session whipsaw gap-through
• Cytokinetics ruling is binary catalyst with 5-10% move in either direction - sitting through it unhedged is uncompensated exposure
• YTD gain of 19.4% should be locked in now rather than waiting for chart cooperation

→ vs aggressive: EPS normalization anchoring ignores strong underlying fundamentals - revenue at record $12.97B, margins intact, FCF $12-14B annually means the operating engine is not broken despite optical multiple compression

→ vs aggressive: Technical alarmism overlooks VWMA at $66.53 still rising, which is the signature of a pullback within an intact uptrend; full Bollinger band walk historically mean-reverts to middle band at $66.24

→ vs aggressive: Pfizer rotation is re-leveraging sector exposure with cosmetic yield enhancement - 200bps pickup does not compensate for introducing correlated binary risks into the portfolio

→ vs aggressive: Waiting for rally to $66 is betting on chart cooperation; with 50 SMA about to break, probability of clean rally is low and conservative risk managers do not make such bets

→ vs aggressive: $57.60 stop at 200 SMA is vulnerable to whipsaw with ATR of $1.50 - single bad session gaps through stop, exiting at $56 or $55

→ vs neutral: Waiting for Q3 confirmation means trim entry point is gone and downside scenario has already played out by the time confirmation arrives

→ vs neutral: Patience is not risk management - sitting through Cytokinetics ruling (10% one-day drawdown risk) with no hedge is uncompensated exposure to scheduled binary catalysts

→ vs neutral: Conservative risk managers act on probability-weighted expectations of identified risks, not wait for confirmation of risks already known

Trim 35-40% of position in two staged tranches; hedge residual exposure with stop at $61-$62 zone; redeploy half freed capital to short-duration Treasuries and half to diversified defensive yield; reject full PFE rotation as correlated sector risk.

• Normalized Q2 EPS ~$1.27 (annualized ~$5), implying 12-13x forward multiple at current prices
• Free cash flow generation $12-14 billion; revenue $12.97 billion (highest quarterly); gross margin 72%
• VWAP $66.53 (rose from $55 in early July), indicating buyers remain in-the-money
• Three binary catalysts within two-month window: Cytokinetics ruling, Eliquis patent news, Q3 earnings
• Short-duration Treasuries yielding 4.5%; BMY yield ~4%
• Current price ~$63.75; 50 SMA one session from breaking; MACD negative
• Middle Bollinger band at $66.24; lower band bounce historically mean-reverts
• Floor reference at $57.60; structural stop zone $61-$62
• YTD gain locked at 19.4%
• PFE rotation adds correlated sector risk with 200bp yield pickup insufficient compensation

→ vs aggressive: EPS distortion argument is valid but doesn't justify 'clear path to high fifties' extrapolation; operating fundamentals (FCF $12-14B, revenue record, 72% margin) remain structurally intact

→ vs aggressive: VWAP still rising at $66.53 means buyers from July remain in-the-money; cherry-picking bearish MACD and Bollinger while ignoring bullish VWMA is confirmation bias, not technical discipline

→ vs aggressive: PFE rotation is not risk reduction—it swaps BMY's patent cliff for Seagen integration risk, cost-cutting narrative, and own competitive pressures; 200bp yield pickup does not compensate for correlated sector exposure

→ vs conservative: Full trim at market at $63.75 assumes zero probability of Bollinger band mean-reversion bounce to $66.24; historical pattern suggests real bounce probability exists

→ vs conservative: 20-30% trim is too modest given three binary catalysts in two-month window; sitting at 60-70% exposure is under-hedged, not conservative

→ vs conservative: Full cash position trades catalyst risk for opportunity cost; with short-duration Treasuries at 4.5% and BMY at 4%, pure cash is also a timing bet